Intranasal Glucagon Could be the First Needle-Free Rescue Treatment for Severe Hypoglycemia INDIANAPOLIS, October 9, 2015 – Eli Lilly and Company (NYSE:LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for … Continued
Data presented in partnership with T1D Exchange at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) support the efficacy and safety of needle-free glucagon nasal powder (GNP) for the treatment of severe hypoglycemia in … Continued
Data presented in partnership with T1D Exchange at the 75th Annual American Diabetes Association (ADA) Scientific Sessions support the efficacy and safety of needle-free glucagon nasal powder (GNP) for the treatment of severe hypoglycemia in youth with type 1 diabetes. … Continued
Preliminary clinical trials have demonstrated that Locemia’s needle-free Glucagon Nasal Powder is as effective as the traditional injected form of glucagon in treating diabetes-related severe hypoglycemia. T1D Exchange scientists are presenting the research this week at the Advanced Technologies & … Continued
Locemia Solutions joined T1D Exchange to present information about a new drug delivery system for emergency hypoglycemia treatment at the 6th Annual Partnering for Cures in New York City. Read the full press release from T1D Exchange.